Lv4
568 积分 2022-06-14 加入
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus
2天前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
8天前
已完结
BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy
21天前
已完结
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases
22天前
已完结
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
1个月前
已完结
Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus
1个月前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
1个月前
已完结
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
1个月前
已完结
CD19 CAR T-Cell Therapy for Autoimmune Hemolytic Anemia
1个月前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
2个月前
已完结
皖公网安备34019202002308
